Cytokinetics Inc (NAS:CYTK)
$ 48.98 -10.25 (-17.31%) Market Cap: 5.14 Bil Enterprise Value: 5.27 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 11, 2021 / 02:45PM GMT
Release Date Price: $20.3 (+3.05%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Good morning, and welcome to day 3 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. I am pleased to welcome Cytokinetics to join me in the next virtual fireside chat. We recently initiated on the company, and they are entering a defining period with a key Phase II readout forthcoming on CK-274 while they're also beginning to gauge with regulators on omecamtiv after positive Phase III data late last year.

Joining -- representing the company is CEO, Robert Blum. Robert, welcome. Thanks for joining us. I believe you're going to start with some opening comments.

Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director

Yes. Thank you, Carter. Thanks for inviting us. I'll share my slides. Tell me if you can see that okay.

Carter Lewis Gould;Robert I. Blum
Barclays Bank PLC, Research Division - Senior Analyst;

Great.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot